Your browser doesn't support javascript.
A SARS-CoV-2 variant with the 12-bp deletion at E gene.
Sun, Yi-Sheng; Xu, Fang; An, Qi; Chen, Chen; Yang, Zhang-Nv; Lu, Hang-Jing; Chen, Jian-Cai; Yao, Ping-Ping; Jiang, Jian-Min; Zhu, Han-Ping.
  • Sun YS; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Xu F; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • An Q; Shanghai King-cell biotechnology Co., Ltd., Shanghai, People's Republic of China.
  • Chen C; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Yang ZN; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Lu HJ; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Chen JC; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Yao PP; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Jiang JM; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Zhu HP; Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
Emerg Microbes Infect ; 9(1): 2361-2367, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-894519
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing and has become an important public health threat. This disease is caused by a new coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and so far, little is known about this virus. In this study, by using plaque purification, we purified two SARS-CoV-2 virus strains from the same specimen, one named F8 containing a 12-bp deletion in the E gene and the other named 8X containing the wild-type E gene. There was no significant difference in the viral titer and infectivity of these two strains. The S protein content of the F8 viral culture was 0.39 µg/ml, much higher than that of 8X. An inactivated vaccine made from the F8 strain could trigger high levels of the IgG titer and neutralizing antibody titer, which could last for at least 6 weeks and were significantly higher than those from the 8X strain at 1 and 3 weeks post vaccination, respectively. In conclusion, we reported that both the E gene mutant and wild-type SARS-CoV-2 strains were isolated from the same clinical sample by plaque purification. A 12-bp deletion in the E gene was important for SARS-CoV-2 replication and immunogenicity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Envelope Proteins / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Envelope Proteins / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2020 Document Type: Article